(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.61%) $79.48
(1.24%) $1.956
(0.81%) $2 329.70
(0.29%) $26.83
(1.33%) $967.60
(-0.01%) $0.933
(-0.04%) $11.03
(-0.08%) $0.798
(0.27%) $93.51
5 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 0.00%
1.05% € 27.97
Live Chart Being Loaded With Signals
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed...
Stats | |
---|---|
Tagesvolumen | 1.08M |
Durchschnittsvolumen | 1.12M |
Marktkapitalisierung | 15.75B |
EPS | €0 ( 2024-02-20 ) |
Nächstes Ertragsdatum | ( €0.700 ) 2024-05-07 |
Last Dividend | €0.920 ( 2023-05-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 44.40 |
ATR14 | €0.0130 (0.05%) |
Volumen Korrelation
Fresenius SE & Co KGaA Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Fresenius SE & Co KGaA Korrelation - Währung/Rohstoff
Fresenius SE & Co KGaA Finanzdaten
Annual | 2023 |
Umsatz: | €22.30B |
Bruttogewinn: | €5.06B (22.68 %) |
EPS: | €-1.050 |
FY | 2023 |
Umsatz: | €22.30B |
Bruttogewinn: | €5.06B (22.68 %) |
EPS: | €-1.050 |
FY | 2022 |
Umsatz: | €40.84B |
Bruttogewinn: | €10.73B (26.26 %) |
EPS: | €2.44 |
FY | 2021 |
Umsatz: | €37.52B |
Bruttogewinn: | €10.31B (27.48 %) |
EPS: | €3.26 |
Financial Reports:
No articles found.
Fresenius SE & Co KGaA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0.920 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.512 | 2000-06-09 |
Last Dividend | €0.920 | 2023-05-18 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | €12.51 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.02 | -- |
Div. Sustainability Score | 6.12 | |
Div.Growth Potential Score | 2.36 | |
Div. Directional Score | 4.24 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PAT.DE | Ex Dividend Junior | 2023-05-26 | Sporadic | 0 | 0.00% | |
ALD.DE | Ex Dividend Knight | 2023-08-10 | Quarterly | 0 | 0.00% | |
HAW.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
SAP.DE | Ex Dividend Knight | 2023-05-12 | Annually | 0 | 0.00% | |
BST.DE | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% | |
KBX.DE | Ex Dividend Knight | 2023-05-08 | Annually | 0 | 0.00% | |
TNE5.DE | Ex Dividend Junior | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
DEF.DE | Ex Dividend Knight | 2023-07-24 | Annually | 0 | 0.00% | |
MSF.DE | Ex Dividend Knight | 2023-08-16 | Quarterly | 0 | 0.00% | |
47T.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0187 | 1.500 | -0.374 | -0.561 | [0 - 0.5] |
returnOnAssetsTTM | -0.0131 | 1.200 | -0.437 | -0.525 | [0 - 0.3] |
returnOnEquityTTM | -0.0298 | 1.500 | -1.443 | -2.16 | [0.1 - 1] |
payoutRatioTTM | -2.07 | -1.000 | -10.00 | 10.00 | [0 - 1] |
currentRatioTTM | 1.342 | 0.800 | 8.29 | 6.63 | [1 - 3] |
quickRatioTTM | 0.729 | 0.800 | -0.419 | -0.335 | [0.8 - 2.5] |
cashRatioTTM | 0.245 | 1.500 | 9.75 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.350 | -1.500 | 4.17 | -6.26 | [0 - 0.6] |
interestCoverageTTM | 2.53 | 1.000 | -0.174 | -0.174 | [3 - 30] |
operatingCashFlowPerShareTTM | 7.91 | 2.00 | 7.36 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.90 | 2.00 | 7.05 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.833 | -1.500 | 6.67 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.233 | 1.000 | 9.45 | 9.45 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0554 | 1.000 | -0.892 | -0.892 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.281 | 1.000 | 9.55 | 9.55 | [0.2 - 2] |
assetTurnoverTTM | 0.702 | 0.800 | 8.65 | 6.92 | [0.5 - 2] |
Total Score | 6.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -26.52 | 1.000 | -2.78 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0298 | 2.50 | -0.927 | -2.16 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.90 | 2.00 | 8.03 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.29 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 7.91 | 2.00 | 7.36 | 10.00 | [0 - 30] |
payoutRatioTTM | -2.07 | 1.500 | -10.00 | 10.00 | [0 - 1] |
pegRatioTTM | 0.468 | 1.500 | -0.210 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.140 | 1.000 | 8.99 | 0 | [0.1 - 0.5] |
Total Score | 2.36 |
Fresenius SE & Co KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.